The May 1, 2021, article by Vasileiou et al entitled “T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects” (*J Clin Oncol* 10.1200/JCO.20.02224) was published with errors.

The AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section read as:

No potential conflicts of interest were reported.

This section should have read as:

Spyridoula Vasileiou

Consulting or Advisory Role: AlloVir

Premal Lulla

Stock and Other Ownership Interests: Johnson & Johnson (I)

Ifigenia Tzannou

Stock and Other Ownership Interests: AlloVir

Ayumi Watanabe

Consulting or Advisory Role: AlloVir

Manik Kuvalekar

Consulting or Advisory Role: AlloVir

Mrinalini Bilgi

Employment: Carsgen Therapeutics Ltd

Carlos Ramos

Consulting or Advisory Role: Novartis

Research Funding: Tessa Therapeutics, Kuur Therapeutics (Inst)

Rayne Rouse

Honoraria: Novartis Pharmaceuticals UK Ltd., Kite/Gilead

Research Funding: Tessa Therapeutics (Inst)

Bambi Grilley

Employment: South Texas Nuclear Pharmacy (I),

Q B Regulatory Consulting

Leadership: AlloVir

Stock and Other Ownership Interests: AlloVir

Travel, Accommodations, Expenses: Tessa Therapeutics

Juan Vera

Employment: Marker Therapeutics

Leadership: Marker Therapeutics, AlloVir

Stock and Other Ownership Interests: Marker Therapeutics, AlloVir

Consulting or Advisory Role: Marker Therapeutics, AlloVir

Research Funding: Marker Therapeutics

Patents, Royalties, Other Intellectual Property: I am an inventor in patents license to Marker Therapeutics Inc and Allovir. Marker Therapeutics Inc is currently advancing a T cell therapy in AML while Allovir is developing T cell therapies for viral infections.

Travel, Accommodations, Expenses: Marker Therapeutics, AlloVir

Catherine Bollard

Leadership: Mana Therapeutics, Cabaletta Bio, Catamaran Bio

Stock and Other Ownership Interests: Mana Therapeutics, Neximmune, Torque, Caballeta Bio, Catamaran Bio

Consulting or Advisory Role: Torque, NexImmune, Cellectis, Cabaletta Bio

Patents, Royalties, Other Intellectual Property: TAA-specific T cells and HIV specific T cells

Open Payments Link

<https://openpaymentsdata.cms.gov/physician/381202>

Malcolm Brenner

Stock and Other Ownership Interests: Bluebird Bio, Tessa Therapeutics, Marker Therapeutics, AlloVir, Walking Fish, Allogene Therapeutics, Memgen, KURR, Bellicum Pharmaceuticals, TScan Therapeutics, Poseida Therapeutics, Abintus Honoraria: Merck (I)

Consulting or Advisory Role: Tessa Therapeutics, Memgen, Torque, NantWorks, Poseida Therapeutics, Cell Medica (I), Formula Pharmaceuticals, Walking Fish Therapeutics, TScan Therapeutics, Alimera Sciences, Marker Therapeutics, Turnstone Bio

Research Funding: Cell Medica (I)

Patents, Royalties, Other Intellectual Property: Not applicable because it's not related.

Travel, Accommodations, Expenses: Merck (I), Tessa Therapeutics, Bluebird Bio, Torque

Helen Heslop

Stock and Other Ownership Interests: Marker Therapeutics, AlloVir

Consulting or Advisory Role: Gilead Sciences, Novartis, Kiadis Pharma, Tessa Therapeutics, Marker Therapeutics, PACT Pharma, Mesoblast

Research Funding: Cell Medica (Inst), Tessa Therapeutics (Inst)

Cliona Rooney

Leadership: Tessa Therapeutics (I)

Stock and Other Ownership Interests: Marker Therapeutics, Marker Therapeutics (I), Bluebird Bio (I), Allovir, Allovir (I)

Consulting or Advisory Role: Tessa Therapeutics, Tessa Therapeutics (I), Alimera Sciences (I), Memgen (I), TScan Therapeutics (I) Research Funding: Tessa Therapeutics

Patents, Royalties, Other Intellectual Property: Takeda, Allogene, Bellicum

Travel, Accommodations, Expenses: Tessa Therapeutics, Tessa Therapeutics (I)

Ann Leen

Stock and Other Ownership Interests: Marker Therapeutics, Allovir

Consulting or Advisory Role: Marker Therapeutics, Allovir Patents, Royalties, Other Intellectual Property: I have patents and pending patents in the field of cell therapy and I have received royalty payments.

Travel, Accommodations, Expenses: Allovir

No other potential conflicts of interest were reported.

This has been corrected as of May 27, 2021. The *Journal of Clinical Oncology* apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.21.01212>